ABOUT TERUMO
The field of cell therapy is a fast-moving, ever-changing landscape. We take pride in leading the way with comprehensive manufacturing strategies, customized solutions and performance-focused products, all backed with the expertise and support to help guide your success.
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
VIDEOS
-
![Medical concept image Blood test GettyImages-1208340299]( "How Terumo Blood And Cell Technologies' Are Advancing Cell and Gene Therapies")
Learn more about the to development of patient-centric innovations to help revolutionize health care and improve clinical outcomes.
-
![Automated Vs Manual Fill And Finish]( "Fill And Finish: Automated Vs Manual")
You've invested a great deal to get your cells to the fill and finish stage. See how see how automating fill and finish reduces risk at this critical step.
-
![Finia Fill And Finish]( "Finia Fill And Finish")
Finia is the first of its kind to automate final formulation and fill and finish for cell therapy manufacturing.
-
![Remaining Complianbt]( "Finia Facts - Reduce The Risk Of Fill And Finish – Remaining Compliant")
Minimize errors. Meet compliance requirements. Learn how the Finia Fill and Finish System automates data capture to facilitate cGMP compliance.
-
![Operator And Product Variability]( "Finia Facts - Reduce The Risk Of Fill And Finish – Operator And Product Variability")
Minimize your variability. Maximize your viability. Optimize your process and ensure product consistency with the Finia Fill and Finish System.
-
![GettyImages-1087219370-fill-finish-aseptic-manufacturing]( "Reduce The Risk Of Fill And Finish – Minimizing Open Events")
Minimize your risk. Maximize your returns. Get your product to those who need it most, when they need it most with the Finia Fill and Finish System.
-
![Terumo Talks]( "Health Economics And Finia Fill And Finish System")
In our new video series, Teru Talks, our experts discuss their points of view on current industry trends, challenges, and opportunities. In our first episode, we’ll discuss the topic of health economics and how it can apply to your business.
CONTACT INFORMATION
Terumo BCT
10810 West Collins Avenue
Lakewood, CO 80215
UNITED STATES
Phone: 877-339-4228
FEATURED WEBINARS
BROCHURES
FEATURED ARTICLES
-
![t cells attacking cancer cell iStock-894635270]( "Elevate Your T-Cell Manufacturing Process")
Today automation and next-generation bioreactors are two prime areas of innovation for enhancing cell manufacturing. Here we delve into some ways these innovations could improve T-cell based therapy production.
-
![iStock-1293772880-lab-science-research-scientist-discovery-development]( "The Monoculture Of Cord-Blood-Derived CD34+ Cells")
Explore an 8-day expansion of a 2 × 10 positively selected CD34+ cell inoculum from 3 donor lineages, and the results proving the automated monoculture protocol can support that expansion with minimal lymphocyte residual.
-
![Intelligent Automation AI]( "Incorporating Automation Into Your Fill And Finish Procedure")
Terumo Blood and Cell Technologies' Global Product Manager for Cell Therapy Technologies explains incorporating automation into fill and finish procedures and it's impact on production costs and product quality.
-
![GettyImages-1275317360-lab-cell-gene-research-scientist-development-discovery]( "Cell Therapy’s Live Analytical Challenges")
Learn about analytical science tools that can be employed to take cell and gene therapy to the next level.
-
![GettyImages-1327977869-lab-cell-biologic]( "Achieve Efficiency And Quality In Cell Therapy Manufacturing")
Enabling automation, reducing manual steps, and implementing standard procedures is key to success in cell therapy manufacturing.
-
![T-cells GettyImages-956478348]( "Large‑Scale Expansion And Characterization Of CD3+ T‑Cells")
We demonstrate a versatile platform for the expansion of T-cells that that reduces time and resources needed to produce a therapeutic dose.
-
![GettyImages-1087219370-fill-finish-aseptic-manufacturing]( "Top Three Reasons Why Automated Data Acquisition Is Critical To Fill And Finish Quality")
Learn how data automation facilitates cGMP compliance and product quality by giving users access to accurate, high-fidelity data to optimize processes and operations.
-
![iStock-525799810-automation]( "Automating Fill And Finish: Five Steps For Scaling Success")
Discover how a solution can help therapeutic providers gain tighter control of their processes and deliver higher-performing treatments compared to manual methods.
NEWS
- Terumo Blood And Cell Technologies Launches Quantum Flex Bioreactor Platform, One Of The First Systems That Enables Cell Therapy Commercialization From Process Development Through Manufacturing
- Terumo Blood And Cell Technologies And GenCure Collaborate To Advance Cell And Gene Therapy Manufacturing Solutions